The groundbreaking rise of Viagra has firmly established as a benchmark of pharmaceutical success, but its legacy within the broader industry now raises questions about potential returns . Copycat versions are eroding patent protection , prompting worries that betting on companies heavily reliant to Viagra's former influence could be a speculative